ES2421717T3 - Fosfatasa alcalina para aumentar la actividad del sistema inmune en un mamífero con riesgo de enfermedades inflamatorias - Google Patents

Fosfatasa alcalina para aumentar la actividad del sistema inmune en un mamífero con riesgo de enfermedades inflamatorias

Info

Publication number
ES2421717T3
ES2421717T3 ES09715588T ES09715588T ES2421717T3 ES 2421717 T3 ES2421717 T3 ES 2421717T3 ES 09715588 T ES09715588 T ES 09715588T ES 09715588 T ES09715588 T ES 09715588T ES 2421717 T3 ES2421717 T3 ES 2421717T3
Authority
ES
Spain
Prior art keywords
alkaline phosphatase
risk
inflammatory diseases
mammal
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09715588T
Other languages
English (en)
Inventor
Rudi Brands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALLOKSYS LIFE SCIENCE BV
Original Assignee
ALLOKSYS LIFE SCIENCE BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALLOKSYS LIFE SCIENCE BV filed Critical ALLOKSYS LIFE SCIENCE BV
Application granted granted Critical
Publication of ES2421717T3 publication Critical patent/ES2421717T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03005—5'-Nucleotidase (3.1.3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Fosfatasa alcalina para utilización en la profilaxis de pacientes sometidos a una intervención quirúrgica, teniendodichos pacientes riesgo de enfermedades inflamatorias como consecuencia de la cirugía, por inducción de fosfatasaalcalina endógena, donde dicha profilaxis comprende la administración intravenosa de una cantidadterapéuticamente eficaz de fosfatasa alcalina a dichos pacientes sometidos a una intervención quirúrgica.
ES09715588T 2008-02-29 2009-02-27 Fosfatasa alcalina para aumentar la actividad del sistema inmune en un mamífero con riesgo de enfermedades inflamatorias Active ES2421717T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2008001767 2008-02-29
PCT/EP2009/001603 WO2009106368A1 (en) 2008-02-29 2009-02-27 Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases

Publications (1)

Publication Number Publication Date
ES2421717T3 true ES2421717T3 (es) 2013-09-05

Family

ID=40723229

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09715588T Active ES2421717T3 (es) 2008-02-29 2009-02-27 Fosfatasa alcalina para aumentar la actividad del sistema inmune en un mamífero con riesgo de enfermedades inflamatorias

Country Status (4)

Country Link
US (1) US8784805B2 (es)
CA (1) CA2716400C (es)
ES (1) ES2421717T3 (es)
WO (1) WO2009106368A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142817A1 (en) * 2004-02-04 2011-06-16 Pharmaaware Sepsis B.V. Means and method for treating and/or preventing necrotizing enterocolitis
JP4999467B2 (ja) 2004-02-04 2012-08-15 ファルマアウェア セプシス ビー．ブイ． 粘膜関門に存在するｌｐｓを解毒するためのアルカリホスファターゼの使用
HRP20080319B1 (hr) * 2005-12-15 2015-11-20 Eli Lilly And Co. Enzimi za smanjenje imunološkog stresa
WO2010025267A2 (en) * 2008-08-29 2010-03-04 The General Hospital Corporation Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase
WO2014052848A1 (en) * 2012-09-28 2014-04-03 The Regents Of The University Of Michigan Apyrase treatments
CA2937328C (en) 2014-01-24 2022-09-27 Am-Pharma B.V. Chimeric alkaline phosphatase-like proteins
ES2810813T3 (es) * 2014-01-24 2021-03-09 Am Pharma Bv Procesamiento para recuperación y purificación de una fosfatasa alcalina
WO2018175413A1 (en) 2017-03-21 2018-09-27 Synthetic Biologics, Inc. Alkaline phosphatase formulations
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
ES3032290T3 (en) 2018-03-20 2025-07-16 Theriva Biologics Inc Intestinal alkaline phosphatase formulations
US11654184B2 (en) 2018-03-20 2023-05-23 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
JP7660523B2 (ja) * 2019-05-06 2025-04-11 セリバ・バイオロジクス・インコーポレイテッド アルカリリン酸塩に基づいた癌治療
US11103628B1 (en) * 2020-04-29 2021-08-31 Orth Consulting, Llc Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005455A1 (en) 1993-08-13 1995-02-23 Rijksuniversiteit Te Groningen Pharmaceutical composition comprising phosphatase or a derivative thereof
WO1996030532A1 (en) 1995-03-24 1996-10-03 Novartis Ag Gene therapy for transplantation and inflammatory or thrombotic conditions
US5852024A (en) * 1997-02-11 1998-12-22 Hadasit Treatment and prevention of adhesions
US7067254B2 (en) 2001-03-01 2006-06-27 Board Of Regents, The University Of Texas System Diagnosis and treatment of inflammation and hyperactive immune conditions
US7534423B2 (en) * 2003-03-28 2009-05-19 Faron Pharmaceuticals Oy Method for inducing an elevated level of adenosine in an individual
JP4999467B2 (ja) * 2004-02-04 2012-08-15 ファルマアウェア セプシス ビー．ブイ． 粘膜関門に存在するｌｐｓを解毒するためのアルカリホスファターゼの使用
EP1942928A2 (en) 2005-10-31 2008-07-16 Essential Skincare, LLC Protein composition for promoting wound healing and skin regeneration
US20090098064A1 (en) 2006-03-17 2009-04-16 Tomas Navratil Method of treating pulmonary edema or pulmonary inflammation

Also Published As

Publication number Publication date
US8784805B2 (en) 2014-07-22
CA2716400C (en) 2017-05-09
WO2009106368A1 (en) 2009-09-03
CA2716400A1 (en) 2009-09-03
US20110052560A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
ES2421717T3 (es) Fosfatasa alcalina para aumentar la actividad del sistema inmune en un mamífero con riesgo de enfermedades inflamatorias
CY1123388T1 (el) Υποκατεστημενου νικοτινιμιδιου αναστολεις της βτκ και παρασκευη αυτων και χρηση στη θεραπεια καρκινου, φλεγμονης και αυτοανοσης ασθενειας
MX391624B (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
MX363007B (es) Uso de n-acetil-5-metoxi-triptamina o analogos de la misma para potenciar el mecanismo de implantacion del embrion, y composiciones y medios de cultivo relacionados.
EP2381957A4 (en) THERAPEUTIC MODULATION OF VAGINAL ELEMENTAL BODY HUMIDIFICATION
MX2013004817A (es) Enfermedad inflamatoria.
BR112015021888A2 (pt) inibidores de dna-ik
UY32668A (es) Agentes inductores de la apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
GT201200315A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
EA201391154A2 (ru) Способы и композиции для нацеливания на адипоциты у млекопитающих
PE20190405A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4beta7
CO7200273A2 (es) Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
IN2014DN08851A (es)
MY186106A (en) Diagnosis, prevention and treatment of diseases of the joint
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
EP2579863A4 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE MASTITIS
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
EA201290603A1 (ru) Способ лечения
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
NI201400122A (es) Agentes terapéuticos para administración subcutánea optimizados
MX378266B (es) Inhibidores de gingipaina de lisina.
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
EA201490862A1 (ru) Осмотически активная система вагинальной доставки